A Phase 2 interventional study of T-817MA and Placebo in Mild Cognitive Impairment, sponsored by FUJIFILM Toyama Chemical Co., Ltd.. Completed at 37 sites in 7 countries. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by FUJIFILM Toyama Chemical Co., Ltd. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Cognitive Dysfunction with a site in Germany — 20 open to participants now, 27 under way, 5 of them phase 3. Cognitive Dysfunction · Germany.
Among the 102 studies in Cognitive Dysfunction with a site in Germany, this one is the 24th largest by enrollment of the 75 interventional ones that give a count, is one of 7 that started in 2019, is one of 8 in phase 2, and was the 62nd registered.
3,885 studies on the registry are indexed under Cognitive Dysfunction; 1,123 are open to participants now.
Browse Cognitive Dysfunction studies →20 of the 102 studies in Cognitive Dysfunction with a site in Germany are open now. Recruiting first, the newest first:
Max Planck Institute for Human Cognitive and Brain Sciences · Sites in Germany
Ages 35–60 · Women only · Healthy volunteers
Henrik Bo Wiberg Larsson · Sites in Germany, Denmark
Ages 50–80 · Healthy volunteers
University Hospital, Bonn · Sites in Germany
Ages 50–80 · Healthy volunteers
University Medicine Greifswald · Sites in Germany
Ages 55–75 · Healthy volunteers
Universitätsklinikum Hamburg-Eppendorf · Sites in Germany
Ages 70+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 751 Cognitive Dysfunction studies recruiting now, 361 (48%) set no upper age limit and 144 (19%) stop at 75 or younger; 46 take children under 18; 260 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 11 · Phase 3 18 · Phase 4 4
First in 2004; this study’s year is marked. 7 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 221 is above the median of 64 across 2,804 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 100 across the 75 interventional studies, 124 across the 27 observational. Of the 58 that completed or were terminated, 14 (24%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 102 have an industry lead sponsor. The 10 most frequent:
FUJIFILM Toyama Chemical Co., Ltd. is the lead sponsor of 5 studies on the registry; none are open to participants now.
FUJIFILM Toyama Chemical Co., Ltd. has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
6 of the studies in Cognitive Dysfunction with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT06207942Region SkaneStepcare Extended Follow-up Substudy | 2027-01 |
| NCT07114458Universitätsklinikum Hamburg-EppendorfDelirium and Cognitive Impairment Development in Hospitalized Older Adults Under Isolation Conditions | 2027-04 |
| NCT06652828University of OldenburgPerturbation-Based Treadmill Training to Prevent Unrecovered Falls in Geriatric Patients | 2027-04-30 |
| NCT07504965Ludwig-Maximilians - University of MunichDementia-friendly Apothecaries as a Resource for Mental Heath in the Elderly | 2027-07-31 |
Add all 6 to your calendar (.ics) → With an account.
Among the 102 studies in Cognitive Dysfunction with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Primary objective is to evaluate the neuroprotective effect of T-817MA on Tau protein phosphorylated at threonine 181 (p-tau 181) in cerebrospinal fluid (CSF) compared with placebo in patients with a diagnosis of MCI due to AD or mild AD.
Secondary objectives are:
To evaluate in patients on T-817MA and placebo:
The criteria were revised on the registry on Nov 20, 2026. See what changed
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: T-817MA
Drug: Placebo
224mg T-817MA orally once daily for first 4 weeks, and then 448mg T-817MA orally once daily for the following weeks.
Placebo once daily
The Change Ratio in the Cerebrospinal Fluid (CSF) p-tau181 From Baseline to Week 78
p-Tau 181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[Week 78 value\]). The changes from Baseline to Week 78 (log\[Week 78 value\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 78 (Week 78 value/Baseline value).
Time frame: Baseline to Week 78
The Change Ratio in the CSF p-tau181 From Baseline to Week 52
p-Tau 181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[Week 52 value\]). The changes from Baseline to Week 52 (log\[Week 52 value\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 (Week 52 value/Baseline value).
Time frame: Baseline to Week 52
The Change Ratio in the CSF p-tau217 From Baseline to Week 52 and 78
p-Tau217 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change Ratio in the CSF Total Tau From Baseline to Week 52 and 78
Total tau was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change Ratio in the CSF Amyloid ß (Aβ) 1-42 From Baseline to Week 52 and 78
Aβ1-42 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change Ratio in the CSF Aβ1-40 From Baseline to Week 52 and 78
Aβ1-40 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change in the CSF Aβ1-42/Aβ1-40 Ratio From Baseline to Week 52 and 78
Aβ1-42/Aβ1-40 ratio was evaluated as a marker for amyloid deposition in the brain.
Time frame: Baseline to Week 52 and 78
The Change Ratio in the CSF Neurofilament Light (NFL) From Baseline to Week 52 and 78
NFL was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change Ratio in the CSF Neurogranin From Baseline to Week 52 and 78
Neurogranin was evaluated as a marker for synaptic damage. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change Ratio in the CSF YKL-40 From Baseline to Week 52 and 78
YKL-40 was evaluated as a marker for inflammatory process driven by glia cells. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change Ratio in the Plasma p-tau181 From Baseline to Week 52 and 78
p-Tau181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change Ratio in the Plasma p-tau217 From Baseline to Week 52 and 78
p-Tau217 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change Ratio in the Plasma Aβ1-42 From Baseline to Week 52 and 78
Aβ1-42 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change Ratio in the Plasma Aβ1-40 From Baseline to Week 52 and 78
Aβ1-40 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change in the Plasma Aβ1-42/Aβ1-40 Ratio From Baseline to Week 52 and 78
Aβ1-42/Aβ1-40 was evaluated as a marker for amyloid deposition in the brain.
Time frame: Baseline to Week 52 and 78
The Change Ratio in the Plasma NFL From Baseline to Week 52 and 78
NFL was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change Ratio in the Plasma Glial Fibrillary Acidic Protein (GFAP) From Baseline to Week 52 and 78
GFAP was evaluated as a marker for inflammatory process driven by glia cells. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
Time frame: Baseline to Week 52 and 78
The Change in Cognitive Function Assessed by Clinical Dementia Rating Scale Sum of Boxes (CDR-sb) From Baseline to Weeks 28, 52, and 78
The CDR is a global rating scale for staging patients diagnosed with dementia. CDR is calculated on the basis of testing six different cognitive and behavioral domains such as memory, orientation, judgment and problem solving, community affairs, home and hobbies performance, and personal care. The CDR is based on a scale of 0-3: no dementia (CDR = 0), questionable dementia (CDR = 0.5), mild cognitive impairment (CDR = 1), moderate cognitive impairment (CDR = 2), and severe cognitive impairment (CDR = 3). The sum of these 6 areas, the CDR-sb score, range from 0 (perfect performance) to 18 (worse).
Time frame: Baseline to Week 28, 52 and 78
The Change in Cognitive Function Assessed by Cognitive Functional Composite (CFC) From Baseline to Weeks 28, 52, and 78
The CFC is expected to detect clinically relevant changes in early dementia stages of AD, and comprises cognitive and functional components. The cognitive composite is computed as a weighted z-score of all seven cognitive subtests: Alzheimer's Disease Assessment Scale-Cognitive Subscale \[ADAS-Cog; 3 subscores (Orientation, Word Recall, Word Recognition), range 0-30\], Digit Span Backward Task (range 0-12), Controlled Oral Word Association Test (1 point for each correct non-repeated word), Category Fluency Test (1 point for each correct unique animal), Digit Symbol Substitution Test (1 point for each correct substituted symbol). The functional component consists of the Amsterdam Instrumental Activity of Daily Living Questionnaire-short version (A-IADL-Q-SV) and the scoring is based on item response theory. The overall CFC score is computed as an equally weighted z-score of the overall cognitive composite and IADL latent trait z-score. (Continued to "Analysis Population Description")
Time frame: Baseline to Week 28, 52 and 78
The Change in Total Brain Volume (TBV) Measured by Volumetric Magnetic Resonance Imaging (vMRI) From Baseline to Weeks 52, and 78
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including mild cognitive impairment (MCI) and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
Time frame: Baseline to Week 52 and 78
The Change in Ventricular Volume Measured by vMRI From Baseline to Weeks 52, and 78
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
Time frame: Baseline to Week 52 and 78
The Change in Hippocampal Volume Measured by vMRI From Baseline to Weeks 52, and 78
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
Time frame: Baseline to Week 52 and 78
The Change in Cortical Thickness (Cortical) Measured by vMRI From Baseline to Weeks 52, and 78
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
Time frame: Baseline to Week 52 and 78
The Change in Cortical Thickness (Medial Temporal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
Time frame: Baseline to Week 52 and 78
The Change in Cortical Thickness (Precuneus) Measured by vMRI From Baseline to Weeks 52, and 78
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
Time frame: Baseline to Week 52 and 78
The Change in Cortical Thickness (Prefrontal Lobe) Measured by vMRI From Baseline to Weeks 52, and 78
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
Time frame: Baseline to Week 52 and 78
The Change in Alpha/Theta Ratio Measured by the Electroencephalogram (EEG) From Baseline to Weeks 52, and 78
An EEG was derived at Baseline and at Weeks 52 and 78 to measure global relative power in the theta band (4 to 8 Hz). Relative theta power has been regarded as the most sensitive marker of EEG oscillatory activity in early AD. In addition, relative power in the alpha band (8 to 13 Hz) and alpha/theta ratio were evaluated. Alpha/theta ratio of the EEG has been reported as a new marker for AD.
Time frame: Baseline to Week 52 and 78
Population Pharmacokinetic (PK) Analysis of T-817MA With Assessment of Maximum Plasma Concentration at Steady State (Css-max)
Blood samples for population PK (PPK) analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual Cmax values of T-817 at steady state (Week 78) were derived and used as Css-max, and then summarized as statistics. Abbreviations of PK parameters are explained in the Analysis Population Description.
Time frame: Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
PPK Analysis of T-817MA With Assessment of Minimum Plasma Concentration at Steady State (Css-min)
Blood samples for population PK (PPK) analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual Cmin values of T-817 at steady state (Week 78) were derived and used as Css-min, and then summarized as statistics.
Time frame: Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
PPK Analysis of T-817MA With Assessment of Area Under the Plasma Concentration-time Curve During a Dosage Interval at Steady State (AUCss-tau)
Blood samples for PPK analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual AUC values of T-817 during a dosage interval at steady state (Week 78) were derived and used as AUCss-tau, and then summarized as statistics.
Time frame: Prior to dosing on the day of the Weeks 28 and 65 clinic visit, and 1 to 6 hours after the time that the last study drug was taken on the scheduled visit day at Weeks 16 and 40.
The Ratio of T-817 Levels in CSF to Plasma (CSF/Plasma)
CSF/plasma Ratio = (Observed CSF concentration of T-817)/(Predicted plasma concentration of T-817). Although the study protocol stated that CSF samples would be collected at Weeks 52 and 78, the actual collections occurred at at least either of Week 52 or Week 78. When the CSF analytical sample at Week 78 was not obtained or the sampling date for Week 78 was not the last T-817 administration date before sampling, the sample at Week 52 or at the point of discontinuation was analyzed. When these samples were not collected closer to the last administration time than the sample at Week 78, the sample at Week 78 was analyzed. CSF concentrations at both of Week 52 and 78 were analyzed for one patient, resulting in a total of 78 data points from 77 individuals, including 28 at Week 52 and 50 at Week 78. Plasma concentrations were predicted by PPK analysis. Individual CSF/plasma ratios at either of Week 52 or/and 78 were derived, pooled and then summarized as statistics.
Time frame: Between 11:00 AM and 2:00 PM on Week 52 and 78.
| Milestone | T-817MA 448 mg | Placebo |
|---|---|---|
| Started | 108 | 113 |
| Completed | 84 | 104 |
| Not completed | 24 | 9 |
| Withdrew: Adverse event | 10 | 3 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Withdrawal by subject | 9 | 5 |
| Withdrew: Noncompliance with study drug | 1 | 0 |
| Withdrew: Other | 1 | 0 |
p-Tau 181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[Week 78 value\]). The changes from Baseline to Week 78 (log\[Week 78 value\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 78 (Week 78 value/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| The Change Ratio in the Cerebrospinal Fluid (CSF) p-tau181 From Baseline to Week 78 | 0.954 ± 0.022 | 0.951 ± 0.020 |
p-Tau 181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[Week 52 value\]). The changes from Baseline to Week 52 (log\[Week 52 value\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 (Week 52 value/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| The Change Ratio in the CSF p-tau181 From Baseline to Week 52 | 0.947 ± 0.022 | 0.963 ± 0.020 |
p-Tau217 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 0.958 ± 0.032 | 1.007 ± 0.032 |
| Week 78 (log-transformed) | 0.953 ± 0.035 | 0.971 ± 0.033 |
Total tau was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 0.971 ± 0.023 | 0.967 ± 0.021 |
| Week 78 (log-transformed) | 0.974 ± 0.023 | 0.963 ± 0.021 |
Aβ1-42 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 0.949 ± 0.029 | 0.966 ± 0.027 |
| Week 78 (log-transformed) | 0.941 ± 0.028 | 0.944 ± 0.025 |
Aβ1-40 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 0.812 ± 0.058 | 0.774 ± 0.051 |
| Week 78 (log-transformed) | 0.808 ± 0.052 | 0.762 ± 0.045 |
Aβ1-42/Aβ1-40 ratio was evaluated as a marker for amyloid deposition in the brain.
| Change in the ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 | 0.016 ± 0.263 | 0.396 ± 0.245 |
| Week 78 | 0.000 ± 0.001 | 0.002 ± 0.001 |
NFL was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 1.175 ± 0.051 | 1.091 ± 0.045 |
| Week 78 (log-transformed) | 1.113 ± 0.043 | 1.118 ± 0.040 |
Neurogranin was evaluated as a marker for synaptic damage. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 0.971 ± 0.020 | 0.980 ± 0.019 |
| Week 78 (log-transformed) | 0.945 ± 0.022 | 0.967 ± 0.021 |
YKL-40 was evaluated as a marker for inflammatory process driven by glia cells. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 1.013 ± 0.014 | 1.023 ± 0.013 |
| Week 78 (log-transformed) | 1.043 ± 0.016 | 1.024 ± 0.015 |
p-Tau181 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 1.079 ± 0.044 | 1.069 ± 0.041 |
| Week 78 (log-transformed) | 1.123 ± 0.040 | 1.051 ± 0.035 |
p-Tau217 was evaluated as a marker for tau pathology (tangle formation). The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 1.056 ± 0.052 | 1.086 ± 0.050 |
| Week 78 (log-transformed) | 1.137 ± 0.050 | 1.063 ± 0.044 |
Aβ1-42 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 0.982 ± 0.048 | 0.981 ± 0.045 |
| Week 78 (log-transformed) | 1.024 ± 0.031 | 1.023 ± 0.029 |
Aβ1-40 was evaluated as a marker for amyloid deposition in the brain. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 1.020 ± 0.045 | 0.971 ± 0.041 |
| Week 78 (log-transformed) | 1.049 ± 0.023 | 1.038 ± 0.021 |
Aβ1-42/Aβ1-40 was evaluated as a marker for amyloid deposition in the brain.
| Change in the ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 | -0.000 ± 0.001 | 0.000 ± 0.001 |
| Week 78 | -0.000 ± 0.001 | 0.000 ± 0.001 |
NFL was evaluated as a marker for neurodegeneration. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 1.185 ± 0.047 | 1.083 ± 0.040 |
| Week 78 (log-transformed) | 1.273 ± 0.048 | 1.084 ± 0.039 |
GFAP was evaluated as a marker for inflammatory process driven by glia cells. The values of the biomarker were converted using a natural logarithm before applying a statistical model to approximate a normal distribution (log\[Baseline value\] and log\[value at Week 52 or 78\]). The changes from Baseline to Week 52 or 78 (log\[value at Week 52 or 78\] - log\[Baseline value\]) were converted back by applying the exponential function, and can be interpreted as the change ratio from Baseline to Week 52 or 78 (\[value at Week 52 or 78\]/Baseline value).
| Ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 (log-transformed) | 1.035 ± 0.032 | 1.042 ± 0.030 |
| Week 78 (log-transformed) | 1.125 ± 0.037 | 1.037 ± 0.032 |
The CDR is a global rating scale for staging patients diagnosed with dementia. CDR is calculated on the basis of testing six different cognitive and behavioral domains such as memory, orientation, judgment and problem solving, community affairs, home and hobbies performance, and personal care. The CDR is based on a scale of 0-3: no dementia (CDR = 0), questionable dementia (CDR = 0.5), mild cognitive impairment (CDR = 1), moderate cognitive impairment (CDR = 2), and severe cognitive impairment (CDR = 3). The sum of these 6 areas, the CDR-sb score, range from 0 (perfect performance) to 18 (worse).
| score on a scale | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 28 | 0.46 ± 0.18 | 0.49 ± 0.17 |
| Week 52 | 1.18 ± 0.23 | 1.03 ± 0.22 |
| Week 78 | 1.53 ± 0.26 | 1.57 ± 0.24 |
The CFC is expected to detect clinically relevant changes in early dementia stages of AD, and comprises cognitive and functional components. The cognitive composite is computed as a weighted z-score of all seven cognitive subtests: Alzheimer's Disease Assessment Scale-Cognitive Subscale \[ADAS-Cog; 3 subscores (Orientation, Word Recall, Word Recognition), range 0-30\], Digit Span Backward Task (range 0-12), Controlled Oral Word Association Test (1 point for each correct non-repeated word), Category Fluency Test (1 point for each correct unique animal), Digit Symbol Substitution Test (1 point for each correct substituted symbol). The functional component consists of the Amsterdam Instrumental Activity of Daily Living Questionnaire-short version (A-IADL-Q-SV) and the scoring is based on item response theory. The overall CFC score is computed as an equally weighted z-score of the overall cognitive composite and IADL latent trait z-score. (Continued to "Analysis Population Description")
| z-score | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 28 | -0.095 ± 0.044 | -0.092 ± 0.042 |
| Week 52 | -0.201 ± 0.052 | -0.223 ± 0.050 |
| Week 78 | -0.366 ± 0.056 | -0.362 ± 0.052 |
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including mild cognitive impairment (MCI) and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
| mm^3 | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 | -14761 ± 1164.3 | -12115 ± 1066.1 |
| Week 78 | -20881 ± 1363.5 | -17892 ± 1233.1 |
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
| mm^3 | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 | 5033.6 ± 378.8 | 3630.1 ± 346.9 |
| Week 78 | 7002.8 ± 438.7 | 5412.9 ± 388.2 |
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
| mm^3 | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 | -120.3 ± 13.2 | -107.9 ± 12.1 |
| Week 78 | -160.6 ± 15.6 | -130.0 ± 14.0 |
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
| mm | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 | -0.045 ± 0.004 | -0.041 ± 0.003 |
| Week 78 | -0.063 ± 0.004 | -0.057 ± 0.004 |
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
| mm | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 | -0.118 ± 0.007 | -0.091 ± 0.007 |
| Week 78 | -0.158 ± 0.009 | -0.142 ± 0.008 |
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
| mm | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 | -0.056 ± 0.005 | -0.049 ± 0.005 |
| Week 78 | -0.077 ± 0.006 | -0.072 ± 0.005 |
Brain structural change is seen in normal aging, but is accelerated in neurodegenerative disease, including MCI and AD. Especially, hippocampal and ventricular volume change over time from MCI to AD. MRI scans and volume calculations were included in the study to investigate the effect of T-817MA on brain atrophy. Longitudinal MRI measures of regional and whole-brain volumetric change provide a valuable complement to cognitive measures in that they are not influenced by temporary symptomatic improvements, and they provide an early index of the study drug's ability to reach the target organ and have an effect on AD-related atrophy.
| mm | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 | -0.042 ± 0.005 | -0.040 ± 0.004 |
| Week 78 | -0.058 ± 0.005 | -0.056 ± 0.004 |
An EEG was derived at Baseline and at Weeks 52 and 78 to measure global relative power in the theta band (4 to 8 Hz). Relative theta power has been regarded as the most sensitive marker of EEG oscillatory activity in early AD. In addition, relative power in the alpha band (8 to 13 Hz) and alpha/theta ratio were evaluated. Alpha/theta ratio of the EEG has been reported as a new marker for AD.
| Change in the ratio | T-817MA 448 mg | Placebo |
|---|---|---|
| Week 52 | 0.031 ± 0.012 | 0.026 ± 0.011 |
| Week 78 | 0.042 ± 0.012 | 0.047 ± 0.011 |
Blood samples for population PK (PPK) analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual Cmax values of T-817 at steady state (Week 78) were derived and used as Css-max, and then summarized as statistics. Abbreviations of PK parameters are explained in the Analysis Population Description.
| ng/mL | T-817MA 448 mg |
|---|---|
| Population Pharmacokinetic (PK) Analysis of T-817MA With Assessment of Maximum Plasma Concentration at Steady State (Css-max) | 612.36 ± 235.96 |
Blood samples for population PK (PPK) analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual Cmin values of T-817 at steady state (Week 78) were derived and used as Css-min, and then summarized as statistics.
| ng/mL | T-817MA 448 mg |
|---|---|
| PPK Analysis of T-817MA With Assessment of Minimum Plasma Concentration at Steady State (Css-min) | 118.13 ± 124.33 |
Blood samples for PPK analysis were collected at Weeks 16, 28, 40, and 65 in MCI due to AD or mild AD Phase 2 study (EU201) with a single blood draw at each of these visits. The PPK analysis was performed on the basis of data collected in the eight Phase 1 studies, two AD Phase 2 studies (JP201 and US202), and EU201 Study (a total of 6753 data from 702 individuals). Population parameters (Ka, LF1, CL/F, Q/F, Vc/F, Vp/F) were calculated considering intra- and inter-individual variability and covariates. Individual post-hoc PK parameters were estimated using the final population parameters and the individual patient data. T-817 plasma concentration-time profiles were predicted by the individual post-hoc PK parameters. Individual AUC values of T-817 during a dosage interval at steady state (Week 78) were derived and used as AUCss-tau, and then summarized as statistics.
| ng*hr/mL | T-817MA 448 mg |
|---|---|
| PPK Analysis of T-817MA With Assessment of Area Under the Plasma Concentration-time Curve During a Dosage Interval at Steady State (AUCss-tau) | 7035.13 ± 3572.12 |
CSF/plasma Ratio = (Observed CSF concentration of T-817)/(Predicted plasma concentration of T-817). Although the study protocol stated that CSF samples would be collected at Weeks 52 and 78, the actual collections occurred at at least either of Week 52 or Week 78. When the CSF analytical sample at Week 78 was not obtained or the sampling date for Week 78 was not the last T-817 administration date before sampling, the sample at Week 52 or at the point of discontinuation was analyzed. When these samples were not collected closer to the last administration time than the sample at Week 78, the sample at Week 78 was analyzed. CSF concentrations at both of Week 52 and 78 were analyzed for one patient, resulting in a total of 78 data points from 77 individuals, including 28 at Week 52 and 50 at Week 78. Plasma concentrations were predicted by PPK analysis. Individual CSF/plasma ratios at either of Week 52 or/and 78 were derived, pooled and then summarized as statistics.
| Ratio | T-817MA 448 mg |
|---|---|
| The Ratio of T-817 Levels in CSF to Plasma (CSF/Plasma) | 0.163 ± 0.166 |
Collected over Screening to Week 82. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| T-817MA 448 mg | 1/108 (0.9%) | 16/108 (14.8%) | 49/108 (45.4%) |
| Placebo | 0/113 (0%) | 14/113 (12.4%) | 41/113 (36.3%) |
| Event | T-817MA 448 mg | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 2/108 | 0/113 |
| Anal abscessInfections and infestations | 1/108 | 0/113 |
| GastroenteritisInfections and infestations | 1/108 | 0/113 |
| MeningitisInfections and infestations | 1/108 | 0/113 |
| Femoral neck fractureInjury, poisoning and procedural complications | 1/108 | 0/113 |
| FractureInjury, poisoning and procedural complications | 1/108 | 0/113 |
| Hand fractureInjury, poisoning and procedural complications | 1/108 | 0/113 |
| Hip fractureInjury, poisoning and procedural complications | 1/108 | 0/113 |
| Joint dislocationInjury, poisoning and procedural complications | 1/108 | 0/113 |
| Pelvic fractureInjury, poisoning and procedural complications | 1/108 | 0/113 |
| Event | T-817MA 448 mg | Placebo |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 18/108 | 8/113 |
| COVID-19Infections and infestations | 18/108 | 18/113 |
| HeadacheNervous system disorders | 8/108 | 9/113 |
| NauseaGastrointestinal disorders | 6/108 | 8/113 |
| Urinary tract infectionInfections and infestations | 6/108 | 7/113 |
| DizzinessNervous system disorders | 3/108 | 7/113 |
| VertigoEar and labyrinth disorders | 6/108 | 2/113 |
| Age, Continuous(years) | T-817MA 448 mg | Placebo | Total |
|---|---|---|---|
| Mean | 70.3 ± 6.1 | 69.2 ± 6.9 | 69.7 ± 6.5 |
| Sex: Female, Male(Participants) | T-817MA 448 mg | Placebo | Total |
|---|---|---|---|
| Female | 63 | 70 | 133 |
| Male | 45 | 43 | 88 |
| Ethnicity (NIH/OMB)(Participants) | T-817MA 448 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 107 | 109 | 216 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | T-817MA 448 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 108 | 113 | 221 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | T-817MA 448 mg | Placebo | Total |
|---|---|---|---|
| Netherlands | 15 | 16 | 31 |
| Czechia | 20 | 22 | 42 |
| Ireland | 3 | 3 | 6 |
| United Kingdom | 9 | 9 | 18 |
| Germany | 24 | 26 | 50 |
| Spain | 37 | 37 | 74 |
| Mini Mental Scale Examination (MMSE) Score(Score on a scale) | T-817MA 448 mg | Placebo | Total |
|---|---|---|---|
| Mean | 26.7 ± 1.8 | 26.6 ± 1.8 | 26.6 ± 1.8 |
| Apolipoprotein E (ApoE) type(Participants) | T-817MA 448 mg | Placebo | Total |
|---|---|---|---|
| E2/E2 | 0 | 1 | 1 |
| E2/E3 | 2 | 1 | 3 |
| E2/E4 | 2 | 0 | 2 |
| E3/E3 | 29 | 36 | 65 |
| E3/E4 | 60 | 60 | 120 |
| E4/E4 | 15 | 15 | 30 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided — Details for sharing data have not been decided yet.
Ran from Dec 2019 to primary completion in Feb 2023, 37 months.
Results were first posted in Nov 2026, 3 years 8 months after primary completion.
Of 42 industry-sponsored phase 2 interventional studies under Cognitive Dysfunction, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 39. This study's 37 months is above that.
Counting every sponsor, half of 187 studies reached it within 42 months; a quarter within 22 and three quarters within 62.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: T-817 maleate
FUJIFILM Toyama Chemical Co., Ltd.